Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!
Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers !
Shipping Price Reduction for EU Regions
This protein carries a polyhistidine tag at the C-terminus
The protein has a calculated MW of 50.6 kDa. The protein migrates as 61-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris,150 mM NaCl,pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Cynomolgus Coagulation factor IX, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Cynomolgus Coagulation factor IX, His Tag(Cat. No. FIX-C52H9) is more than 90% and the molecular weight of this protein is around 55-75 kDa verified by SEC-MALS.
Measured by its ability to cleave the fluorogenic peptide substrate, Mca-RPKPVE-Nval-WRK(Dnp)-NH2 . The specific activity is >30 pmol/min/μg (QC tested).
Price(EUR) : €400.00
Price(EUR) : €1520.00
Price(EUR) : €5660.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Anti-inhibitor coagulant complex (Baxalta) | Approved | Baxalta Incorporated | Feiba, Prothromplex TOTAL | United States | Hemophilia A; Hemophilia B | Baxalta Incorporated | 1979-12-21 | Blood Coagulation Disorders; Blood Coagulation Disorders, Inherited; Hemophilia A; Hemophilia B; Cardiovascular Diseases | Details | |
Human prothrombin complex (Nanyue Biopharming) | Approved | Hunan Ziguang Huhan Nanyue Pharmaceutical Co Ltd | Mainland China | Hemorrhage | Hunan Ziguang Huhan Nanyue Pharmaceutical Co Ltd | 2019-09-05 | Hemophilia B; Hemorrhage | Details | ||
Eptacog alfa (Novo Nordisk) | NN-007 | Approved | Novo Nordisk A/S | NiaStase, NovoSeven, 诺其 | EU | Factor VII Deficiency; Hemophilia A; Hemophilia B; Thrombasthenia | Novo Nordisk A/S | 1996-02-23 | Cerebral Hemorrhage; Spinal Diseases; Hemophilia A; Hemophilia B; Fibrosis; Hemorrhage; Stroke; Postpartum Hemorrhage; Factor VII Deficiency; Severe Dengue; Burns; Wounds and Injuries; Blood Loss, Surgical; Thrombasthenia; Acquired hemophilia | Details |
Etranacogene dezaparvovec | AAV5-hFIX; AMT-061; CSL-222; AMT-060 | Approved | University College London, Uniqure Biopharma Bv | HEMGENIX | United States | Hemophilia B | Csl Behring | 2022-11-22 | Hemophilia B | Details |
Human prothrombin complex (CSL Behring) | BE-1116 | Approved | Csl Behring Llc | Kcentra, Beriplex, Confidex | Blood Coagulation Disorders; Coagulation Protein Disorders; Heart Failure; Heart Diseases; Hemorrhage; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Wounds and Injuries | Details | ||||
Freeze-dried activated human blood coagulation factor Ⅶ concentrate containing factor Ⅹ (Kaketsuken/KM Biologics) | MC-710 | Approved | Kaketsuken | Byclot | Japan | Hemophilia A | null | 2014-07-04 | Hemophilia A | Details |
Human prothrombin complex concentrate (Guizhou Taibang Biological Products) | Approved | Guizhou Taibang Biological Products Co Ltd | Mainland China | Hypoprothrombinemias | Guizhou Taibang Biological Products Co Ltd | 2013-07-31 | Hypoprothrombinemias | Details | ||
Prothrombinex-VF (CSL Behring) | Approved | Csl Behring Llc | Australia | Hemorrhage | Csl Behring Llc | 2014-10-01 | Hemorrhage | Details | ||
Fidanacogene elaparvovec | SPK-9001; PF-06838435 | Approved | The Children'S Hospital Of Philadelphia | BEQVEZ | Canada | Hemophilia B | Pfizer Inc | 2024-01-03 | Hemophilia A; Hemophilia B | Details |
Prothrombin complex concentrate (Sanquin) | Approved | Sanquin Plasma Products Bv | Cofact | Hemorrhage | Sanquin Plasma Products Bv | 2007-11-01 | Hemorrhage | Details | ||
Emicizumab | RG-6013; ACE-910; RO-5534262 | Approved | Genentech Inc, Chugai Pharmaceutical Co Ltd | 舒友立乐, Hemlibra | United States | Hemophilia A | Genentech Inc | 2017-11-16 | Hemophilia A; Hemorrhage; von Willebrand Disease, Type 3 | Details |
Factor XP Behring (CSL Behring) | Approved | Csl Behring Llc | Spain | Factor X Deficiency | Csl Behring Llc | 2015-09-01 | Factor X Deficiency | Details | ||
Eptacog alfa biosimilar (AryoGen Biopharma) | Approved | Aryogen Biopharma | Iran | Factor VII Deficiency; Hemophilia A; Hemophilia B; Thrombasthenia | Aryogen Biopharma | 2014-01-01 | Hemophilia A; Hemophilia B; Factor VII Deficiency; Thrombasthenia | Details | ||
Factor IX complex (Grifols) | Approved | Grifols Sa | Profilnine | United States | Hemophilia B | null | 1981-07-21 | Intracranial Hemorrhages; Hemophilia B | Details | |
Eptacog beta | LR-769; rhFVIIa | Approved | Lfb Biotechnologies Sas, Revo Biologics Inc | Sevenfact | United States | Hemophilia A; Hemophilia B | Lfb Biotechnologies Sas | 2020-04-01 | Hemophilia A; Hemophilia B | Details |
Human prothrombin complex (Octapharma) | Approved | Octapharma | Ocplex, Octaplex, Pronativ | Germany | Hemorrhage | Octapharma | 2003-03-14 | Hemorrhage; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Eptacog alfa biosimilar (International Biotech Center Generium) | GNR-001 | Approved | International Biotech Center Generium | Russian Federation | Hemophilia A | International Biotech Center Generium | 2015-01-01 | Hemophilia A | Details | |
Human prothrombin complex (LFB) | Approved | Lfb Biotechnologies Sas | KANOKAD | France | Hemorrhage | Lfb Biotechnologies Sas | 2008-09-01 | Hemorrhage | Details | |
Human prothrombin complex (Tonrol Biopharmaceuticals) | Approved | Tonrol Bio-Pharmaceutical Co Ltd | ProthoRAAS | Mainland China | Hemorrhage | Shanghai Raas Blood Products Co Ltd | 1996-01-01 | Hemophilia B; Hemorrhage | Details | |
Human prothrombin complex (Guangdong Shuanglin) | Approved | Guangdong Shuanglin Bio-Pharmaceutical Co Ltd | Mainland China | Hemophilia B | Guangdong Shuanglin Bio-Pharmaceutical Co Ltd | 2023-05-12 | Hemophilia B | Details | ||
Human prothrombin complex (Shanghai Xinxing) | Approved | Shanghai Xinxing Medicine Co Ltd | Mainland China | Hemorrhage | Shanghai Xinxing Medicine Co Ltd | 1997-01-01 | Hemorrhage | Details | ||
Human prothrombin complex (Sinopharm Shanghai Plasma) | Approved | Sinopharm Shanghai Plasma-Derived Biotherapies Co Ltd | Mainland China | Hemorrhage | Sinopharm Shanghai Plasma-Derived Biotherapies Co Ltd | 1997-01-01 | Hemorrhage | Details | ||
Human prothrombin complex (Boya Bio-Pharmaceutical) | Approved | Boya Bio-Pharmaceutical Group Co Ltd | Mainland China | Hemorrhage | Boya Bio-Pharmaceutical Group Co Ltd | 2020-12-02 | Hemophilia B; Hemorrhage | Details | ||
Human prothrombin complex (Guangdong Wellen) | Approved | Guangdong Wellen Pharmaceutical Co Ltd | Mainland China | Hemorrhage | Guangdong Wellen Pharmaceutical Co Ltd | 2020-10-21 | Hemophilia B; Hemorrhage | Details | ||
Factor IX (Octapharma ) | Approved | Octapharma | EU | Hemophilia B | Octapharma | 2001-12-23 | Hemophilia B | Details | ||
Human prothrombin complex(Hebei Daan Pharmaceutical) | Approved | Hebei Daan Pharmaceutical Co Ltd | Mainland China | Hemorrhage | Hebei Daan Pharmaceutical Co Ltd | 2020-01-01 | Hemophilia B; Hemorrhage | Details | ||
Prothrombin complex concentrat (Taibang Biological Products) | Approved | Shandong Taibang Biological Products Co Ltd | Mainland China | Hemorrhage | Shandong Taibang Biological Products Co Ltd | 2014-09-30 | Hemorrhage; Antithrombin III Deficiency | Details | ||
Human prothrombin complex (Hualan Biological Engineering) | Approved | Hualan Genetic Engineering Co Ltd | Mainland China | Blood Coagulation Disorders; Factor X Deficiency | Hualan Biological Engineering Inc | 1999-01-01 | Blood Coagulation Disorders; Hemophilia B; Factor X Deficiency | Details | ||
Human prothrombin complex concentrate (Shanxi Kangbao Biological Products) | Approved | Shanxi Kangbao Biological Product Co Ltd | Mainland China | Hemorrhage | Shanxi Kangbao Biological Product Co Ltd | 2019-09-17 | Hemophilia B; Hemorrhage | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Mim8 | Mim8; NN7769; NNC0365-3769; NN-7769 | Phase 3 Clinical | Novo Nordisk A/S | Hemophilia A | Details |
Eptacog Alfa Biosimilar(Aryogen Pharmed) | Phase 3 Clinical | Aryogen Pharmed Co | Hemophilia A; Factor VII Deficiency | Details | |
CT-001 (Coagulant Therapeutics) | CT-001; CT001 | Phase 3 Clinical | Coagulant Therapeutics Corp | Pain; Postpartum Hemorrhage | Details |
Human prothrombin complex concentrate (Sichuan Yuanda Shuyang Pharmaceutical) | Phase 3 Clinical | Sichuan Yuanda Shuyang Pharmaceutical Co Ltd | Blood Coagulation Disorders | Details | |
BBM-H901 | BBM-H901 | Phase 3 Clinical | Belef BioMed (Shanghai) Co Ltd | Hemophilia B | Details |
Human prothrombin complex concentrate (Harbin Shiheng Bioengineering Pharmaceutical) | Phase 3 Clinical | Harbin Pacific Biopharmaceutical Co Ltd | Hemophilia B | Details | |
Human prothrombin complex (Lanzhou Lansheng Blood Products) | Phase 3 Clinical | Lanzhou Lansheng Blood Products Co Ltd | Hemophilia B | Details | |
Recombinant human coagulation factor VIIa (Chengdu Rongsheng Pharmaceuticals) | Phase 3 Clinical | Chengdu Rongsheng Pharmaceuticals Co Ltd | Hemophilia A | Details | |
Human prothrombin complex(Hunan Ziguang Huhan Nanyue Pharmaceutical) | Phase 3 Clinical | Hunan Ziguang Huhan Nanyue Pharmaceutical Co Ltd | Hemophilia B | Details | |
aPCC-emicizumab | Phase 3 Clinical | Emory University | Hemophilia A | Details | |
Dalcinonacog alfa | ISU304; ISU-304; CB-2679d | Phase 2 Clinical | Catalyst Bioscience | Hemophilia B | Details |
BAX-335 | BAX-335; AskBio-009 | Phase 2 Clinical | Glaxosmithkline Plc, Asklepios BioPharmaceutical Inc, Bayer AG | Hemophilia B | Details |
Factor VIIa-CTP | MOD-5014; MOD-5017; OPK88005 | Phase 2 Clinical | Opko Health Inc, Prolor Biotech | Blood Coagulation Disorders, Inherited; Hemophilia A; Hemophilia B | Details |
FT-004 | FT-004; FT004 | Phase 2 Clinical | Frontera Therapeutics (Shanghai) Co Ltd | Hematologic Diseases; Hemophilia B | Details |
ZS-801 | ZS801; ZS-801 | Phase 2 Clinical | Sichuan Zhishan Weixin Biotechnology Co Ltd | Hemophilia B | Details |
ANB-002 | ANB-2; ANB-002 | Phase 2 Clinical | Biocad | Hemophilia B | Details |
VGB-R04 | VGB-R04 | Phase 2 Clinical | Shanghai Vitalgen BioPharma Co Ltd | Hemophilia B | Details |
Eptacog alfa biosimilar (Valin Technologies) | Phase 1 Clinical | Valin Technologies | Hemophilia A | Details | |
Marzeptacog alfa | CB-813; CB-813d; PF-5280602; PF-05280602 | Phase 1 Clinical | Catalyst | Hemophilia A; Hemophilia B | Details |
AAV2-hFIX16 | AAV2-hFIX16 | Phase 1 Clinical | Spark Therapeutics Inc | Hemophilia B | Details |
SS-327 | GenSciences-327; 注射用培重组人凝血因子IX-Fc融合蛋白; SS327 | Phase 1 Clinical | Zhengzhou Shengsi Biotechnology Co Ltd, Furen Pharmaceutical Group Co Ltd | Hemophilia B | Details |
JWK-004 | JWK004; JWK-004 | Phase 1 Clinical | Chengdu Genevector Therapeutics Co Ltd | Hemophilia B | Details |
Human prothrombin complex (National Drug Group Wuhan Blood) | Phase 1 Clinical | National Drug Group Wuhan Blood Products Co Ltd | Hemorrhage | Details | |
YUVA-GT-F901 | YUVA-GT-F901 | Phase 1 Clinical | Novartis Pharma Ag | Hemophilia B | Details |
This web search service is supported by Google Inc.